Theravance Biopharma Halts Clinical Program for Ampreloxetine
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy TBPH?
Source: seekingalpha
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.000
Low
13.00
Averages
28.40
High
42.00
Current: 14.000
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: Investors considering buying VMC stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainty.
- Source of Information: This information is provided by Benzinga, highlighting the potential impact of analyst ratings on the market, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Theravance Biopharma's Phase 3 Trial Fails to Meet Primary Endpoint
- Pivotal Trial Failure: Theravance Biopharma's CYPRESS Phase 3 study did not meet its primary endpoint, leading to the termination of the ampreloxetine program, which significantly pressured the stock price, resulting in a 27.05% drop to $13.82.
- Accelerated Strategic Restructuring: The company's board is expediting its strategic review process, impacting about 50% of its workforce, with one-time severance costs estimated between $5 to $7 million, aiming to reduce operating expenses by approximately 60% year-over-year.
- Poor Market Performance: Currently, Theravance's stock is trading 27.34% below its 52-week high, reflecting significant volatility, and the absence of effective technical analysis indicators complicates short-term outlook assessments.
- Future Earnings Outlook: Theravance is set to report earnings on March 17, 2026, with an EPS estimate of 34 cents and revenue forecast of $41.74 million, indicating signs of recovery from previous losses, although the forward P/E ratio of 33.2x suggests a premium valuation.
See More
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
- Trial Failure: Theravance Biopharma's CYPRESS study failed to achieve statistical significance on its primary endpoint, leading to the decision to wind down the program, which is expected to have a significant negative impact on future revenues.
- Workforce and Cost Cuts: The company announced a 50% reduction in its workforce and plans to cut operating expenses by about 60%, anticipating one-time cash severance expenses of $5 million to $7 million over the next two quarters.
- Sales Outlook: Despite the challenges, Theravance expects global net sales to reach at least $3.51 billion in 2026, indicating the potential of its product YUPELRI in treating chronic obstructive pulmonary disease.
- Stock Reaction: Theravance's shares plunged nearly 30% following the announcement, breaking below the 200-day moving average for the first time, reflecting the market's pessimism regarding the company's future prospects.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Dynamics Overview: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Focus: Investors considering buying VMC stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainty.
- Source of Information: This information is provided by Benzinga, highlighting the potential impact of analyst ratings on the market, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Theravance Biopharma's Phase 3 Trial Fails to Meet Primary Endpoint
- Pivotal Trial Failure: Theravance Biopharma's CYPRESS Phase 3 study did not meet its primary endpoint, leading to the termination of the ampreloxetine program, which significantly pressured the stock price, resulting in a 27.05% drop to $13.82.
- Accelerated Strategic Restructuring: The company's board is expediting its strategic review process, impacting about 50% of its workforce, with one-time severance costs estimated between $5 to $7 million, aiming to reduce operating expenses by approximately 60% year-over-year.
- Poor Market Performance: Currently, Theravance's stock is trading 27.34% below its 52-week high, reflecting significant volatility, and the absence of effective technical analysis indicators complicates short-term outlook assessments.
- Future Earnings Outlook: Theravance is set to report earnings on March 17, 2026, with an EPS estimate of 34 cents and revenue forecast of $41.74 million, indicating signs of recovery from previous losses, although the forward P/E ratio of 33.2x suggests a premium valuation.
See More
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
- Trial Failure: Theravance Biopharma's CYPRESS study failed to achieve statistical significance on its primary endpoint, leading to the decision to wind down the program, which is expected to have a significant negative impact on future revenues.
- Workforce and Cost Cuts: The company announced a 50% reduction in its workforce and plans to cut operating expenses by about 60%, anticipating one-time cash severance expenses of $5 million to $7 million over the next two quarters.
- Sales Outlook: Despite the challenges, Theravance expects global net sales to reach at least $3.51 billion in 2026, indicating the potential of its product YUPELRI in treating chronic obstructive pulmonary disease.
- Stock Reaction: Theravance's shares plunged nearly 30% following the announcement, breaking below the 200-day moving average for the first time, reflecting the market's pessimism regarding the company's future prospects.
See More
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
- Dow Jones Plummets: The Dow Jones index fell over 900 points on Tuesday, down 1.85% to 48,002.16, reflecting market sensitivity to geopolitical risks amid the ongoing Iran-U.S. conflict.
- NASDAQ and S&P 500 Decline: The NASDAQ dipped 1.80% to 22,338.43, while the S&P 500 dropped 1.65% to 6,768.35, indicating investor concerns about market outlook.
- Commodity Market Fluctuations: Oil prices surged 8.4% to $77.23 per barrel, driven by supply disruption fears, while gold and silver fell 3.3% and 8.2%, respectively, suggesting a decrease in safe-haven demand.
- European Markets Decline: The eurozone's STOXX 600 index fell 3.2%, and Spain's IBEX 35 index dropped 4.8%, reflecting global market reactions to the downturn in U.S. stocks, which may impact investor confidence.
See More
Theravance Biopharma Halts Clinical Program for Ampreloxetine
- Clinical Trial Setback: Theravance Biopharma announced the halt of its clinical program for ampreloxetine due to the Phase 3 CYPRESS study failing to meet its primary endpoint, resulting in a trading halt for the company's shares and negatively impacting investor confidence.
- Cost Reduction Initiative: The company is implementing a cost reduction program that will involve layoffs of approximately 50% of its workforce, allowing it to focus on its FDA-approved COPD treatment, Yupelri, and achieve nearly a 60% reduction in operating expenses this year.
- Future Cash Flow Projections: Theravance projects an annualized cash flow of $60 million to $70 million starting in Q3 2026 from Yupelri sales, indicating potential profitability post-restructuring despite current setbacks.
- Market Reaction: The failure of the clinical trial and the layoff plan may exert further pressure on Theravance's stock price, prompting investors to closely monitor how the company adjusts its strategy to navigate these challenges.
See More
